A carregar...
Concurrence of nivolumab‐induced interstitial lung disease and cancer invasion
Nivolumab improves overall survival rates of patients with advanced or recurrent non‐small‐cell lung cancer (NSCLC). Among immune‐related adverse events caused by nivolumab, interstitial lung disease (ILD) is a clinically serious and potentially life‐threatening toxicity, for which appropriate treat...
Na minha lista:
| Publicado no: | Respirol Case Rep |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley & Sons, Ltd
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5553297/ https://ncbi.nlm.nih.gov/pubmed/28811904 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/rcr2.257 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|